Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum
Resource type
Journal Article
Authors/contributors
- Ljungman, Per (Author)
- Chemaly, Roy F (Author)
- Khawaya, Fareed (Author)
- Alain, Sophie (Author)
- Avery, Robin (Author)
- Badshah, Cyrus (Author)
- Boeckh, Michael (Author)
- Fournier, Martha (Author)
- Hodowanec, Aimee (Author)
- Komatsu, Takashi (Author)
- Limaye, Ajit P (Author)
- Manuel, Oriol (Author)
- Natori, Yoichiro (Author)
- Navarro, David (Author)
- Pikis, Andreas (Author)
- Razonable, Raymund R (Author)
- Westman, Gabriel (Author)
- Miller, Veronica (Author)
- Griffiths, Paul D (Author)
- Kotton, Camille N (Author)
- for the CMV Definitions Working Group of the Transplant Associated Virus Infections Forum (Author)
Title
Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum
Abstract
Cytomegalovirus (CMV) infection and disease are important causes of morbidity and mortality in transplant recipients. For the purpose of developing consistent reporting of CMV outcomes in clinical trials, definitions of CMV infection and disease were developed and most recently published in 2017. Since then, there have been major developments, including registration of new antiviral agents. Therefore, the Transplant Associated Virus Infections Forum, which consists of scientists, clinicians, regulators, and industry representatives, has produced an updated version of these definitions that incorporates recent knowledge with the aim of supporting clinical research and drug development. This also includes an update regarding the definition of resistant and refractory CMV infections previously published in 2019. As the field evolves, the need for updates of these definitions is clear, and collaborative efforts among clinicians, scientists, regulators, and industry representatives can provide a platform for this work.
Publication
Clinical Infectious Diseases
Pages
ciae321
Date
2024-07-23
Journal Abbr
Clinical Infectious Diseases
ISSN
1058-4838
Short Title
Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials
Accessed
7/27/24, 12:51 PM
Library Catalog
Silverchair
Citation
Ljungman, P., Chemaly, R. F., Khawaya, F., Alain, S., Avery, R., Badshah, C., Boeckh, M., Fournier, M., Hodowanec, A., Komatsu, T., Limaye, A. P., Manuel, O., Natori, Y., Navarro, D., Pikis, A., Razonable, R. R., Westman, G., Miller, V., Griffiths, P. D., … for the CMV Definitions Working Group of the Transplant Associated Virus Infections Forum. (2024). Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum. Clinical Infectious Diseases, ciae321. https://doi.org/10.1093/cid/ciae321
Link to this record